Study 1 (Profile 1007) Flashcards
1
Q
Study design
A
Randomized, multicenter, open label, active controlled study
2
Q
Total number of patients
A
347
3
Q
Patients had been previously treat with………
A
one platinum based chemotherapy regimen
4
Q
Xalkori dose
A
250mg BID
5
Q
of Xalkori pts
A
173
6
Q
of chemo pts
A
174
7
Q
Type of chemo used
A
Pemetrexed 500 (if naïve to it) or Docetaxil 75 intravenous every 21 days
8
Q
OS
A
not reached
9
Q
after progression ……….number and % of chemo patients received Xalkori
A
112 (64%)
10
Q
ORR vs chemo
A
65% vs. 20%
11
Q
Duration of response vs chemo
A
7.4 months vs. 5.6
12
Q
Progression free survival vs. chemo
A
7.7 vs. 3.0
13
Q
Eye disorder %
A
60%
14
Q
Diarrhea %
A
60%
15
Q
Nausea %
A
55%
